Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Levoleucovorin Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0104

    Levoleucovorin and Leucovorin Agents

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0104 alerts

    Get alerted when Policy CC-0104 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-benefit clinical review and prior authorization for injectable levoleucovorin and leucovorin agents, including Khapzory and Vykoura, for methotrexate rescue or toxicity reduction, selected oncology indications, anemia, and graft-versus-host disease prophylaxis.

    Policy Summary
    PayerEmpire Bluecross
    PolicyLevoleucovorin and Leucovorin Agents
    Policy CodePolicy CC-0104
    Change TypeModified
    Effective DateApril 22, 2026
    Last ReviewMar 9, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization requests with documentation that the patient meets a covered indication or oncology criterion.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Vykoura based on product labeling and NCCN recommendations.

    Revised oncology criteria for levoleucovorin and leucovorin agents.

    Updated step therapy to include Vykoura.

    Updated ICD-10-CM diagnosis coding.

    Updated HCPCS coding for Vykoura.

    Removed HCPCS J0640.

    2Drug products with separate criteria sets
    OR-basedCoverage logic

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NCCN 2A
    Evidence category for multiple oncology uses
    Under 19Age-based approval criterion
    Not coveredRequests outside listed criteria

    Covered Uses and Exclusions

    Levoleucovorin Agents — Initial Therapy

    Covered when ANY of the following criteria are met:

    ONE of

    • Individual is under 19 years of age.
    • Individual is using levoleucovorin as a component of high-dose methotrexate therapy in osteosarcoma.
    • Individual is using levoleucovorin as a treatment of impaired methotrexate elimination.
    • Individual is using levoleucovorin as a treatment of inadvertent over-dosage of folic acid antagonists.
    • Individual is using levoleucovorin in combination chemotherapy with fluorouracil-based regimens to treat colorectal adenocarcinoma.
    • Individual is using levoleucovorin in combination with high-dose methotrexate when leucovorin is not available in pediatric acute lymphoblastic leukemia or pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma, diffuse B-cell lymphoma, primary mediastinal large B-cell lymphoma, and pediatric posttransplant lymphoproliferative disorders (NCCN 2A).
    • Individual is using levoleucovorin in combination with high-dose methotrexate when leucovorin is not available for the management of symptomatic Bing-Neel syndrome in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (NCCN 2A).
    • Individual is using levoleucovorin in combination with chemotherapy for ONE of the following cancers (NCCN 2A):

      • Acute lymphoblastic leukemia (ALL).
      • Acute myeloid leukemia (AML), including blastic plasmacytoid dendritic cell neoplasm (BPDCN).
      • Anal carcinoma.
      • Ampullary adenocarcinoma.
      • Appendiceal neoplasms and cancers, including appendiceal adenocarcinoma, undifferentiated carcinoma not otherwise specified, goblet cell adenocarcinoma, low-grade appendiceal mucinous neoplasm, and high-grade appendiceal mucinous neoplasm.
      • B-cell lymphoma, including follicular lymphoma (grade 1-2), diffuse large B-cell lymphoma, high-grade B-cell lymphomas (NOS), post-transplant lymphoproliferative disorders, HIV-related B-cell lymphomas, or Burkitt lymphoma.

    Vykoura — Initial Therapy

    Covered when ANY of the following criteria are met:

    ONE of

    • Individual is under 19 years of age.
    • Individual is using Vykoura as rescue after high-dose methotrexate therapy.
    • Individual is using Vykoura to reduce the toxicity of methotrexate in individuals with impaired methotrexate elimination.
    • Individual is using Vykoura to reduce the toxicity of folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose.
    • Individual is using Vykoura in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible.

    Initial and Disease-Specific Covered Indications

    Covered when ANY of the following disease-specific oncology criteria are met:

    ONE of

    • Individual is using Vykoura in combination with fluorouracil-based regimens for ONE of the following cancer diagnoses (NCCN 2A):

      • Pancreatic adenocarcinoma, adenosquamous carcinoma, or squamous carcinoma.
      • Biliary tract cancers, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma.
      • Ovarian cancers, including mucinous neoplasms of the ovary.
      • Neuroendocrine and adrenal tumors, including pancreatic neuroendocrine tumors (well-differentiated grade 1/2 or grade 3) and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine-non-neuroendocrine neoplasm.

    Requests for levoleucovorin agents (levoleucovorin calcium, Khapzory) may not be approved when the above criteria are not met and for all other indications.

    Requests for Vykoura (leucovorin injection) may not be approved when the above approval criteria are not met and for all other indications.

    Vykoura requests for indications other than the listed age-based, clinical, oncology-related, and prophylaxis criteria are not approved.

    Initial Therapy Requirements

    Initial Therapy: Covered Indications

    Initial requests are covered when any one of the following indications is met:

    Initial therapy indications: The individual is using the agent for methotrexate rescue; toxicity reduction; folate-deficiency anemia when oral therapy is not feasible; metastatic colorectal cancer in combination with 5-fluorouracil; a specified NCCN 2A oncology regimen using fluorouracil-based chemotherapy or high-dose methotrexate; or graft-versus-host disease prophylaxis in combination with methotrexate.

    The listed indications are alternative qualifying uses.

    Billing and Diagnosis Codes

    Levoleucovorin HCPCSHCPCS
    J0641Injection, levoleucovorin, not otherwise specified, 0.5 mg. [levoleucovorin calcium]
    J0642Injection, levoleucovorin 0.5 mg [Khapzory]
    Leucovorin Agents HCPCSHCPCS
    C9310Injection, leucovorin calcium (Avyxa), 1 mg [Vykoura]
    J3490Unclassified drugs [when specified as Vykoura (leucovorin calcium)]
    ICD-10 DiagnosisICD-10
    B20Human immunodeficiency virus [HIV] disease
    C15.3-C17.9Malignant neoplasm of esophagus, stomach, small intestine
    C18.0-C21.8Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal
    C22.1Intrahepatic bile duct carcinoma
    C23Malignant neoplasm of gallbladder
    C24.1Malignant neoplasm of ampulla of Vater
    C24.0Malignant neoplasm of extrahepatic bile duct
    C24.8Malignant neoplasm of overlapping sites of biliary tract
    C24.9Malignant neoplasm of biliary tract, unspecified
    C25.0-C25.9Malignant neoplasm of pancreas
    1–10 of 56
    1/6
    HCPCS codes mentioned in document historyHCPCS
    J0641HCPCS code added in the 2019 coding review.
    J0642HCPCS code added effective October 1, 2019.
    J3490HCPCS code deleted effective October 1, 2019.
    C9043Injection, levoleucovorin; added in the 2019 coding review and deleted effective January 1, 2020.

    Authorization and Documentation Requirements

    Prior Authorization

    Clinical Review Required

    When a drug is reviewed under the member's medical benefit or is otherwise subject to clinical review, including prior authorization, apply the applicable medical-necessity criteria to the intended or prescribed use.

    Documentation Required

    Submit Prior Authorization for Covered Use

    Submit prior authorization with documentation supporting the covered use of the requested agent. Requests that do not meet the applicable criteria, or that are for other indications, may not be approved.

    • Identify the requested agent: levoleucovorin calcium, Khapzory, or Vykoura (leucovorin injection).
    • Document the treatment indication, oncology diagnosis where applicable, regimen, and relevant treatment details.
    • For Vykoura, document the applicable covered use, including rescue or toxicity reduction, folic-acid-deficiency megaloblastic anemia when oral therapy is not feasible, fluorouracil-based therapy, high-dose methotrexate-based therapy, or qualifying oncology use.

    Clinical Background

    Leucovorin is folinic acid, a derivative of folic acid. Levoleucovorin is the biologically active l-isomer of leucovorin and is dosed at one-half the dose of racemic d,l-leucovorin. These agents may reduce toxicity or counteract impaired elimination of folic-acid antagonists such as methotrexate and may enhance the effects of fluoropyrimidines such as 5-fluorouracil in cancer treatment. The policy includes FDA-approved uses and additional oncology uses supported by NCCN category 2A recommendations.

    Terms and Concepts

    Definitions
    TermAnalogue
    DefinitionA drug or substance which is similar to, but not identical, to another drug or substance.
    Policy contextThe term describes similarity between drugs or substances without identity.
    Definitions
    TermAntagonist
    DefinitionAn agent which blocks the binding of an agonist at a receptor site.
    Receptor actionThe agonist is a substance that binds to a specific receptor and triggers a response in the cell.

    Step-Therapy Requirements

    StepAgentRequirement details
    1Vykoura (leucovorin calcium)Existing step-therapy requirements were updated to include Vykoura. The preceding steps and failure requirements are not specified in the available policy excerpt.
    Policy Summary
    PayerEmpire Bluecross
    PolicyLevoleucovorin and Leucovorin Agents
    Policy CodePolicy CC-0104
    Change TypeModified
    Effective DateApril 22, 2026
    Last ReviewMar 9, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization requests with documentation that the patient meets a covered indication or oncology criterion.
    SourceLink
    On This Page
    Covered Uses and ExclusionsInitial Therapy RequirementsBilling and Diagnosis CodesAuthorization and Documentation RequirementsClinical BackgroundTerms and ConceptsStep-Therapy Requirements
  1. Bladder cancer.
  2. Bone cancer, including osteosarcoma, dedifferentiated chondrosarcoma, and high-grade undifferentiated pleomorphic sarcoma.
  3. Central nervous system (CNS) cancers, including primary CNS lymphoma, limited brain metastases, extensive brain metastases, or leptomeningeal metastases.
  4. Cervical cancer.
  5. Chronic lymphocytic leukemia/small lymphocytic lymphoma.
  6. Esophageal and esophagogastric junction cancers.
  7. Gastric cancer.
  8. Gestational trophoblastic neoplasia.
  9. Biliary tract cancers, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma.
  10. Neuroendocrine and adrenal tumors, well-differentiated grade 3 NET, including poorly differentiated (high grade)/large or small cell tumors.
  11. Occult primary.
  12. Ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, including mucinous carcinoma.
  13. Pancreatic adenocarcinoma.
  14. Small bowel adenocarcinoma.
  15. T-cell lymphomas, including hepatosplenic T-cell lymphoma, peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma, or extranodal NK/T-cell lymphoma.
  16. Thymomas and thymic carcinomas.
  17. Vaginal cancer.
  18. Individual is using Vykoura in combination with 5-fluorouracil in the treatment of metastatic colorectal cancer.
  19. Individual is using Vykoura as prophylaxis in combination with methotrexate for graft versus host disease (DrugDex BIIa).
  20. Thymomas and thymic carcinomas.
  21. Occult primary tumors, including squamous cell carcinoma, adenocarcinoma, or carcinoma not otherwise specified.
  22. Cervical cancer, including squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma.
  23. Bladder cancer, including non-urothelial and urothelial tumors with subtype histology, and pure adenocarcinoma including urachal cancer.
  24. Esophageal and esophagogastric junction cancers.
  25. Gastric cancer.
  26. Vaginal cancer.
  27. Small bowel adenocarcinoma.
  28. Anal carcinoma.
  29. Appendiceal neoplasms and cancers, including appendiceal adenocarcinoma, undifferentiated carcinoma not otherwise specified, goblet cell adenocarcinoma, low-grade appendiceal mucinous neoplasm, and high-grade appendiceal mucinous neoplasm.
  30. Ampullary adenocarcinoma.
  31. Individual is using Vykoura in combination with high-dose methotrexate for ONE of the following cancer diagnoses (NCCN 2A):

    • Pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma, diffuse B-cell lymphoma, primary mediastinal large B-cell lymphoma, and pediatric post-transplant lymphoproliferative disorders.
    • Waldenström macroglobulinemia/lymphoplasmacytic lymphoma for management of symptomatic Bing-Neel syndrome.
    • Pediatric acute lymphoblastic leukemia.
    • Pediatric Langerhans cell histiocytosis.
    • Gestational trophoblastic neoplasia.
    • Central nervous system (CNS) cancers, including primary CNS lymphoma, brain metastases, and leptomeningeal metastases.
    • Acute lymphoblastic leukemia (ALL).
    • Bone cancer, including osteosarcoma, dedifferentiated chondrosarcoma, and high-grade undifferentiated pleomorphic sarcoma.
    • Acute myeloid leukemia (AML), including blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  32. Step Therapy

    Vykoura Added to Step Therapy

    Vykoura has been added to the existing step-therapy requirements for levoleucovorin and leucovorin-agent requests. Verify and document completion of applicable prerequisite therapy before requesting Vykoura.

    • Apply step therapy to Vykoura (leucovorin injection) as well as the existing agents.
    • Include the relevant prior-treatment history and the clinical rationale for the requested agent.
    Documentation Required

    Clinical Indication and Treatment Documentation

    For levoleucovorin calcium or Khapzory, document the patient's age, diagnosis or treatment indication, chemotherapy regimen, and treatment details. Covered uses include patients younger than 19; high-dose methotrexate rescue or treatment of impaired methotrexate elimination; treatment of inadvertent folic-acid-antagonist overdose; fluorouracil-based treatment of colorectal adenocarcinoma; and qualifying chemotherapy-based oncology indications.

    • Document age when the request relies on the under-19 criterion.
    • Document high-dose methotrexate use for osteosarcoma; pediatric acute lymphoblastic leukemia; pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma, diffuse B-cell lymphoma, primary mediastinal large B-cell lymphoma, and pediatric post-transplant lymphoproliferative disorders; symptomatic Bing-Neel syndrome in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma; or other qualifying cancer diagnoses.
    • For combination chemotherapy indications, document the cancer diagnosis, regimen, and NCCN 2A-supported use. Covered diagnoses include ALL, AML/BPDCN, anal, ampullary, appendiceal, B-cell lymphoma, bladder, bone, CNS, cervical, CLL/SLL, esophageal/esophagogastric-junction, gastric, gestational trophoblastic, biliary tract, neuroendocrine/adrenal, occult-primary, ovarian/fallopian-tube/primary-peritoneal, pancreatic, small-bowel, T-cell lymphoma, thymic, and vaginal cancers.
    Documentation Required

    Vykoura Clinical Indication and Treatment Details

    For Vykoura, document the requested agent, the oncology diagnosis or other indication, and the complete treatment plan. Covered documentation may support methotrexate rescue, toxicity reduction, folic-acid-deficiency megaloblastic anemia when oral therapy is not feasible, fluorouracil-based treatment, high-dose methotrexate-based treatment, or qualifying oncology therapy.

    • Methotrexate-related uses: rescue after high-dose methotrexate or toxicity reduction for impaired methotrexate elimination.
    • Overdose-related use: toxicity reduction for folic-acid antagonists or DHFR inhibitors.
    • Oncology documentation: specify the diagnosis and regimen, including fluorouracil-based treatment of pancreatic, biliary tract, ovarian, neuroendocrine/adrenal, thymic, occult-primary, cervical, bladder, esophageal/esophagogastric-junction, gastric, vaginal, small-bowel, anal, appendiceal, or ampullary cancers.
    • High-dose methotrexate documentation: specify the diagnosis, including pediatric aggressive mature B-cell lymphoma, symptomatic Bing-Neel syndrome, pediatric ALL, pediatric Langerhans cell histiocytosis, gestational trophoblastic neoplasia, CNS cancer, ALL, bone cancer, or AML/BPDCN.
    • Other covered use: prophylaxis in combination with methotrexate for graft-versus-host disease.
    Denial Risk

    Unlisted Levoleucovorin Indication

    Levoleucovorin-agent requests may not be approved when the applicable criteria are not met or when the requested use is not listed as covered.

    • Review the indication against the covered age, diagnosis, chemotherapy, and treatment criteria before submission.
    • Provide clinical documentation for any criterion relied upon; an unmet or unsupported criterion creates denial risk.
    Denial Risk

    Unlisted Vykoura Indication

    Vykoura requests may not be approved when the applicable criteria are not met or when the requested use is not listed as covered.

    • Ensure the requested diagnosis, regimen, and treatment details match a covered Vykoura indication.
    • Document the applicable methotrexate, fluorouracil, oncology, anemia, overdose, or graft-versus-host-disease use.
    Denial Risk

    Unmet Criteria May Result in Denial

    Vykoura may not be approved when the applicable criteria are unmet, the requested indication is unlisted, or the submission lacks sufficient clinical support.

    • Confirm that the requested use satisfies the applicable clinical indication and treatment criteria.
    • Include documentation supporting the diagnosis, regimen, requested agent, and any required prior therapy.
    Billing Rule

    Codes Do Not Guarantee Coverage

    Procedure, diagnosis, and device codes listed for this policy are informational only and do not guarantee member coverage or provider reimbursement.

    • Determine coverage and non-coverage under the member's contract benefits in effect at the time of service.
    • Code inclusion or exclusion does not establish medical necessity, coverage, or reimbursement.
    Definitions
    TermChemotherapy
    DefinitionMedical treatment of a disease, particularly cancer, with drugs or other chemicals.
    Primary applicationThe definition particularly identifies cancer treatment.
    Definitions
    TermMetastasis
    DefinitionThe spread of cancer from one part of the body to another.
    Metastatic tumorA metastatic tumor contains cells like those in the original (primary) tumor that have spread.
    Definitions
    TermNeuroendocrine tumor (NET)
    DefinitionA tumor that forms from cells that release hormones into the blood in response to a signal from the nervous system.
    Clinical behaviorNETs may make higher-than-normal amounts of hormones and may be benign or malignant.
    Definitions
    TermNCCN 2A
    MeaningNational Comprehensive Cancer Network category 2A recommendation.
    Policy applicationThe policy identifies specified fluorouracil-based and high-dose methotrexate oncology indications as NCCN 2A recommendations.
    Definitions
    TermMethotrexate rescue
    DefinitionUse of levoleucovorin or leucovorin after high-dose methotrexate therapy to reduce methotrexate toxicity.
    Policy indicationThe policy lists use as a rescue after high-dose methotrexate therapy as a covered indication.